Abstract
The present disclosure relates, in part, to risankizumab compositions having a reduced level of hitchhiker protein PLA2, Poloxamer 188, and/or decreased immunogenicity.
Source: Autobound Signal API · 112 signals tracked for AbbVie · updated
Get AbbVie's live signals in Claude or ChatGPT, or by API
What changed at AbbVie this week? Use Autobound signals for abbvie.com.In November 2026 AbbVie patented risankizumab formulations for pharmaceutical use, designed to reduce unwanted proteins, processing additives, and immune reactions.
Abstract
The present disclosure relates, in part, to risankizumab compositions having a reduced level of hitchhiker protein PLA2, Poloxamer 188, and/or decreased immunogenicity.
What this signalsA new patent often shows where a company is putting its R&D budget.
Tags
Technologies named
patents-companypatentGrantGet every patent signal for AbbVie and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/b227c98d-06c0-5b28-8f85-0b30a7d0c9d5 returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "b227c98d-06c0-5b28-8f85-0b30a7d0c9d5",
"signal_type": "patents-company",
"signal_subtype": "patentGrant",
"detected_at": "2026-11-18T15:07:43+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"cpc": [
{
"code": "C07K 16/244"
},
{
"code": "A61K 9/0019"
},
{
"code": "A61K 9/08"
},
{
"code": "A61K 38/465"
},
{
"code": "A61K 39/3955"
}
],
"tags": [
"Intellectual Property",
"Research & Development",
"Pharmaceuticals",
"Medical Research"
],
"detail": "In November 2026 AbbVie patented risankizumab formulations for pharmaceutical use, designed to reduce unwanted proteins, processing additives, and immune reactions.",
"summary": "AbbVie was granted a patent for improved risankizumab compositions.",
"event_at": "2026-11-17",
"inventors": [
{
"name": "Liqiang Zhou",
"status": "resolved",
"is_primary": true,
"linkedin_url": "https://www.linkedin.com/in/liqiang-lisa-zhou-166a6b32"
}
],
"event_kind": "grant_date",
"grant_date": "2026-11-17",
"source_url": "https://patents.google.com/patent/US12799192",
"cpc_primary": {
"code": "C07K 16/244"
},
"patent_title": "Risankizumab compositions",
"patent_number": "US12799192",
"uspto_assignee": "ABBVIE INC.",
"patent_abstract": "The present disclosure relates, in part, to risankizumab compositions having a reduced level of hitchhiker protein PLA2, Poloxamer 188, and/or decreased immunogenicity.",
"precision_class": "structural",
"invention_explanation": "A formulation of risankizumab made with fewer unwanted protein contaminants and additives to help reduce the chance of an immune response.",
"technologies_mentioned": [
"risankizumab",
"antibody formulations",
"biopharmaceutical manufacturing"
]
}
}
curl https://signals.autobound.ai/v1/signals/b227c98d-06c0-5b28-8f85-0b30a7d0c9d5 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.